Macrogenics (MGNX) Tops Q3 EPS by 7c

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 10/23/2026

1. RNG
2. DECK
3. WDC
4. BYD
5. SPOT
6. WCN
7. BMY
8. TSCO
9. BE
10. SPY

Go back to Macrogenics (MGNX) Tops Q3 EPS by 7c

MacroGenics Provides Update on Corporate Progress and Third Quarter 2019 Financial Results

November 6, 2019 4:01 PM EST

ROCKVILLE, Md., Nov. 06, 2019 (GLOBE NEWSWIRE) -- MacroGenics, Inc. (NASDAQ: MGNX), a clinical-stage biopharmaceutical company focused on discovering and developing innovative monoclonal antibody-based therapeutics for the treatment of cancer, today provided an update on its corporate progress and reported financial results for the quarter ended September 30, 2019.

MacroGenics most advanced programs are positioned to initiate or complete registration-directed studies over the next year, said Scott Koenig, M.D., Ph.D., President and CEO of MacroGenics. We look forward to presenting detailed data from the second interim OS analysis of SOPHIA, the Phase 3 study comparing... More